The West AustralianCSL has agreed to pay as much as $2.3 billion to jointly develop and sell an experimental treatment for kidney and liver diseases.
CSL to pay $2.3b in lixudebart disease drug deal with Alentis Therapeutics
From the report
How outlets headlined it
Each outlet's own headline. Struck through: the loaded words our version leaves out. Plainest first.
-
The West Australian
CSL to pay $2.3b in lixudebart
raredisease drug deal with Alentis Therapeutics 1 change -
The Motley Fool Australia
CSL unveils exclusive Alentis deal to advance
raredisease treatments 1 change
Headline as published: CSL to pay $2.3b in lixudebart rare disease drug deal with Alentis Therapeutics
This is a summary. The indicators are not. The scores were measured over this summary alone, which is less of the article than we would like and makes them less certain.
How each outlet filed it
| Outlet | Niral Score | Adjectives | Sourcing | Political | Sentiment | Happiness |
|---|---|---|---|---|---|---|
| The West Australianas they published this story | 18 | 2 | 42 | 0 | -0.2 | 41.3 |
| The Motley Fool Australia | 18.2 | 15 | 31 | -0.2 | -0.1 | 45.5 |
How did this read?
Sign in to react.
Comments
Comments are not open yet. They will be once there is someone to read every one before it appears. If something here is wrong, tell us — that we do read.
Report a problem with these scores or this rewrite — it goes straight into the public ledger.
The same event elsewhere
1 other outlet filed this story. The scoreboard above is what they did differently.